Skip to main content
OpenTrials
Completed

NCT Number: NCT02857374

Intravital Microscopy in Identifying Tumor Vessels in Patients With Stage IB-IIIC Melanoma Undergoing Sentinel Lymph Node Biopsy

This pilot clinical trial studies intravital microscopy in identifying tumor vessels in patients with stage IB-IIIC melanoma undergoing sentinel lymph node biopsy. By examining sentinel lymph nodes through intravital microscopy before they are removed, doctors may learn specific information regarding how melanoma may spread to lymph nodes and other sites of the body.

Completed

Looking for future studies?

Notify Me

Key information

About this study

PRIMARY OBJECTIVES:

I. To determine the feasibility of intravital microscopy in characterizing the microvasculature of the sentinel lymph node (SLN) in melanoma patients requiring SLN biopsy.

SECONDARY OBJECTIVES:

I. To identify vascular blood flow parameters and flow kinetics associated with the sentinel lymph node vasculature and define the utility of using commonly used fluorescent agents during human intravital microscopy and correlate with clinical outcomes (time to recurrence, survival), as a potential basis for a novel prognostic tool and/or microstaging technique.

TERTIARY OBJECTIVES:

I. To determine the relationship between live microscopically-recorded images and pathology slides in terms of vessel density and vessel diameter.

OUTLINE:

Patients receive indocyanine green and fluorescein sodium injection intravenously (IV) and then undergo intravital microscopic observation over 15-20 minutes during standard of care sentinel node biopsy.

After completion of study treatment, patients are followed up at 3 weeks and then every 6 months for 5 years or every 3 months for 2 years and every 6 months for another 2 years.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of =< 2
  • Melanoma tumor that meets indications for a groin SLN biopsy with a >= 10% risk of having metastasis to the draining lymph node (i.e. stage IB to stage IIIC melanoma of the lower body below the umbilicus)
  • Participant must be eligible for a groin sentinel lymph node (SLN) biopsy
  • Participant or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure

Exclusion criteria

  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Sentinel lymph node is deemed inaccessible to microscopic observation during the operative procedure (i.e. sentinel node maps to a deep location or area outside of the groin)
  • Renal dysfunction as defined as creatinine clearance < 70 mL/min by Cockroft-Gault equation
  • Any known allergy or prior reaction to fluorescein, indocyanine green, iodine, or shellfish
  • Unwilling or unable to follow protocol requirements
  • Any condition which in the Investigator's opinion deems the participant an unsuitable candidate to undergo observational study (may also include preoperative testing results including electrocardiogram [EKG], chest x-ray, or pulmonary function tests)
  • Any condition that excludes SLN biopsy as the standard of care (e.g. lymphadenectomy indicated)

Treatment and study plan

Diagnostic Microscopy

Procedure

Undergo intravital microscopy

Fluorescein Sodium Injection

Drug

Given IV

Other names: AK-Fluor, Fluorescite

laboratory biomarker analysis

Other

Correlative studies

Sentinel Lymph Node Biopsy

Procedure

Undergo standard of care sentinel node biopsy

Other names: Sentinel Node Biopsy, Sentinel node biopsy alone, SLNB, SNB

Primary outcomes

  1. Feasibility of intravital microscopy in characterizing the microvasculature of the SLN in melanoma determined by successful visualization of at least 6 of 10 patients during Part I

    Time frame: Up to 3 weeks

    The visualization method will be deemed successful in patients with tumor vessel identification, measurement of tumor vessel diameters, determining vessel density, and visualizing fluorescein/indocyanine green within the tumor vessels.

Secondary outcomes

  1. Flow kinetics associated with the sentinel lymph node vasculature

    Time frame: Up to 5 years

    Sample sentinel lymph node characteristics obtained from the intervention will be characterized using descriptive statistics (means, medians) and 95% confidence intervals.

  2. Survival

    Time frame: Up to 5 years

    Assessed using Kaplan Meier and Proportional Hazards methods. Collected through routine follow-up processes.

  3. Time to progression

    Time frame: Up to 5 years

    Assessed using Kaplan Meier and Proportional Hazards methods. Collected through routine follow-up processes.

  4. Treatment response

    Time frame: Up to 5 years

    Assessed using Logistic Regression. Collected through routine follow-up processes.

  5. Utility of using commonly used fluorescent agents during human intravital microscopy

    Time frame: Up to 3 weeks

  6. Vascular blood flow parameters associated with the sentinel lymph node vasculature

    Time frame: Up to 5 years

    Sample sentinel lymph node characteristics obtained from the intervention will be characterized using descriptive statistics (means, medians) and 95% confidence intervals.

Other outcomes

  1. Blood vessel density and diameter assessed from live microscopically-recorded images and from pathology slides

    Time frame: Up to 5 years

    The relationship between the live microscopically-recorded images and the pathology slides in terms of vessel density and vessel diameter will be determined. Correlations between microscopic observations (vessel diameter, density, blood flow velocity, vessel hierarchy tissue penetration of fluorescein/indocyanine green) with pathologic node positivity and clinical outcomes (time to recurrence, survival) will be analyzed.

Sponsors and collaborators

Lead sponsor

Roswell Park Cancer Institute

Other

Registry information

Official study title

Intravital Microscopy (IVM) During Sentinel Lymph Node (SLN) Biopsy for Melanoma

Important dates

Study start
2016
Primary completion
2018
Study completion
2022
First posted
Aug 5, 2016
Registry last updated
Aug 1, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.